And especially in cancer.

Well, I think the career in medicine is a very noble career.

Sometimes we lose sight of that.

But mostly in oncology, there is a great access to collaboration.

There is an influx of science of understanding the human body in a better way of not just giving toxin, but utilizing molecular biology and immunology, which are the basic tenets of medicine.

In order to help patients.

So the amount of novel therapeutics that target the immune system, that target the tumor microenvironment, that target genetic changes in our cells has exploded.

Where are we? Where is the civilization approaching the cure?

So next question is, what advancements are most exciting to you right now?

Well, as far as advancements, I think this understanding that we now have about targeting The tumor, so the idea data that's come is interesting.

We're going to really have to understand where it belongs in the setting for HLA-2 positive patients versus HLA-2 negative patients.

The ability to do TIL.

Not as a standard, but to understand its role and to get more data is important and we're actively actively asking some of these companies to you know dip their toe and fall in.

the impacts whether it's tabenta fuss or brunetta fuss uh they're they're interesting on their own and as we move forward to the uh tcr t therapies like the ematics trial what is mind-blowing now is that there are multiple randomized trials ongoing that may lend itself to approvals or access whether it's the rp2 drug from replimune or the ematics drug or some of the novel stuff that's coming from immunocore and their impact platform or the antibody drug conjugates that looked very promising but is now in a holding pattern at Novartis.

Those things will help us understand the metastatic paradigm and we'll have more than just one or two tools.

Oh my goodness.